Pulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $16.33.

Several research analysts have commented on the stock. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $14.00 price objective (down from $16.00) on shares of Pulmonx in a research note on Friday, February 23rd. Canaccord Genuity Group dropped their price target on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. Piper Sandler reissued an “overweight” rating and issued a $17.00 price objective on shares of Pulmonx in a research report on Wednesday, April 3rd. Citigroup boosted their target price on Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, Stifel Nicolaus raised their price target on Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd.

Insider Activity at Pulmonx

In other Pulmonx news, CEO Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.60, for a total transaction of $292,000.00. Following the transaction, the chief executive officer now owns 1,121,344 shares of the company’s stock, valued at approximately $16,371,622.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Pulmonx news, insider Geoffrey Beran Rose sold 3,097 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $9.06, for a total value of $28,058.82. Following the completion of the transaction, the insider now directly owns 239,952 shares in the company, valued at $2,173,965.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.60, for a total transaction of $292,000.00. Following the completion of the sale, the chief executive officer now owns 1,121,344 shares in the company, valued at $16,371,622.40. The disclosure for this sale can be found here. Insiders sold 39,032 shares of company stock worth $469,012 over the last three months. 5.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after purchasing an additional 7,316 shares during the last quarter. Strs Ohio purchased a new stake in Pulmonx during the 3rd quarter worth approximately $85,000. Quest Partners LLC acquired a new position in Pulmonx during the 4th quarter valued at approximately $94,000. Aigen Investment Management LP purchased a new position in shares of Pulmonx in the third quarter worth $111,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Pulmonx during the fourth quarter worth $117,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Stock Performance

Shares of NASDAQ:LUNG opened at $9.28 on Tuesday. The firm has a fifty day simple moving average of $8.58 and a two-hundred day simple moving average of $10.73. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $357.65 million, a P/E ratio of -6.03 and a beta of 0.66. Pulmonx has a 52 week low of $7.11 and a 52 week high of $14.84.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $18.85 million during the quarter, compared to analyst estimates of $17.54 million. Pulmonx had a negative return on equity of 46.61% and a negative net margin of 80.46%. During the same quarter last year, the business posted ($0.42) earnings per share. On average, analysts expect that Pulmonx will post -1.63 earnings per share for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.